VICTORIA, British Columbia – IMMUNOPRECIDED ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in the discovery and development of full-service therapeutic antibodies, announced today that Dr. Yasmina Abdiche, Chief Scientific Officer, will resign effective July 1, 2021 to pursue other opportunities, and that the board of directors has appointed Dr. Ilse Roodink to assume the position of scientific director
Since 2019, Dr. Ilse Roodink has served as Chair of the Scientific Advisory Committee for Talem Therapeutics and has been instrumental in leading IPA’s SARS-CoV-2 Polytope ™.Cocktail program, acting as the Company’s Global COVID-19 Project Manager. In her simultaneous role as Scientific Director, she has overseen the execution and management of contract research projects at the company’s Dutch facility in Oss. Dr. Roodink is also actively involved in integrating innovative technologies that support antibody discovery, characterization, and engineering.
Prior to the API, Dr. Roodink worked at ModiQuest Research, which was acquired by the Company in 2018. Dr. Roodink received his Ph.D. from Radboud University Nijmegen and continued his studies as a post-doctoral researcher developing a in vitro platform for isolating single domain antibodies that specifically recognize native tumor targets, scientific areas in which he has made significant contributions through research and peer-reviewed publications.
Dr. Jennifer Bath, Executive Director of IPA, stated that “On behalf of the IPA, we would like to congratulate Dr. Roodink on his appointment as Chief Scientific Officer. His experience, drive and leadership have supported many facets of IPA’s success in advancing the company’s CRO services and developing the internal pipeline, including its COVID programs. ”
“I would like to thank Dr. Abdiche for his contributions to our progress and we wish him all the best in his future endeavors,” concluded Dr. Baño.
About ImmunoPrecise Antibodies Ltd.
IPA is an innovation-driven technology platform company that supports its pharmaceutical and biotechnology partners in their quest to discover and develop novel therapeutic antibodies against all classes of target diseases. The company aims to transform the conventional, multi-vendor product development model by bringing innovative, high-throughput, data-driven technologies to its partners, incorporating the advantages of diverse antibody repertoires with the suite of therapeutic antibody discovery technologies. from the company, to exploit antibodies of broad epitope coverage, multiple antibody formats, valence and size, and to discover antibodies against multiple / rare epitopes. For more information visit www.immunoprecise.com or contact [email protected]
Email: [email protected]